Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Mar-Apr;20(2):195-8.
doi: 10.4103/2230-8210.176355.

Effects of gliclazide add on metformin on serum omentin-1 levels in patients with type 2 diabetes mellitus

Ali I Al-Gareeb  1 , Haidar F Alrubai  2 , Sammar M Suliaman  3
Affiliations

Effects of gliclazide add on metformin on serum omentin-1 levels in patients with type 2 diabetes mellitus

Ali I Al-Gareeb et al. Indian J Endocrinol Metab. 2016 Mar-Apr.

Abstract

Background: Omentin is a newly identified adipokine that has beneficial influence against cardiovascular disorders. Hence, considering the impact of anti-diabetic drug on omentin levels may provide an adjuvant strategy to protect diabetic patients against valuable clinical hazards.

Aim of the study: To investigate the influence of metformin alone or in combination with gliclazide on the level of serum omentin among patients with type 2 diabetes mellitus (T2DM).

Patients and methods: A total of 70 newly diagnosed patients with T2DM were enrolled in this randomized, double-blind prospective study, and divided into two equal groups based on treatment regimen in which Group 1 treated with metformin (1000 mg) and Group 2 treated with metformin (1000 mg) plus gliclazide (80 mg). Blood glucose levels, HbA1C, insulin levels, and serum omentin-1 were measured at baseline and after 12 weeks of treatment.

Result: Use of gliclazide as an add-on therapy to metformin in patients with T2DM result in better glycemic control evidenced by significant reductions in the levels of blood glucose levels and HbA1C and much more improvement in insulin sensitivity evidenced by significant decreased in insulin resistance index, whereas it has adverse impact on serum omentin-1 levels evidenced by significant decrement in omentin-1 level in comparison to their pretreatment levels among Group 2 patients.

Conclusions: Adding of gliclazide to metformin in treatment of patients with T2DM might extend the therapeutic action of metformin in regarding much better controlling of glycemic indices, but, at the same time, it might attenuate the cardioprotective effects of metformin by its adverse influence on serum omentin-1 levels.

Keywords: Diabetes mellitus; gliclazide; metformin; omentin-1.

PubMed Disclaimer

References

    1. Piero MN, Nzaro GM, Njagi JM. Diabetes mellitus – A devastating metabolic disorder. Asian J Biomed Pharm Sci. 2014;4:1–7.
    1. Maiese K. mTOR: Driving apoptosis and autophagy for neurocardiac complications of diabetes mellitus. World J Diabetes. 2015;6:217–24. - PMC - PubMed
    1. Gastaldelli A. Role of beta-cell dysfunction, ectopic fat accumulation and insulin resistance in the pathogenesis of type 2 diabetes mellitus. Diabetes Res Clin Pract. 2011;93(Suppl 1):S60–5. - PubMed
    1. Jaikanth C, Gurumurthy P, Cherian KM, Indhumathi T. Emergence of omentin as a pleiotropic adipocytokine. Exp Clin Endocrinol Diabetes. 2013;121:377–83. - PubMed
    1. Lu Y, Zhou L, Liu L, Feng Y, Lu L, Ren X, et al. Serum omentin-1 as a disease activity marker for Crohn's disease. Dis Markers 2014. 2014:162517. - PMC - PubMed